Title: Risk Factors Associated with Increased Antibiotic Use in COVID-19 Hospitalized Patients

Authors: Alysa J. Martin, PharmD[1]#; Stephanie Shulder, PharmD, BCIDP[1]; David Dobrzynski,
MD[2]; Katelyn Quartuccio, PharmD, BCPS[3]; Kelly E. Pillinger, PharmD, BCPS-AQ ID, BCIDP[1]

[1] University of Rochester Medical Center Strong Memorial Hospital, Department of Pharmacy,
Rochester, NY, USA

[2] University of Rochester Medical Center, Division of Infectious Diseases, Rochester, NY, USA

[3] University of Rochester Medical Center Highland Hospital, Department of Pharmacy,
Rochester, NY, USA

 # Address correspondence to: Alysa J. Martin, PharmD, alysa_martin@urmc.rochester.edu

Running title: COVID-19 antibiotic risk factors

Key words: COVID-19, antimicrobial stewardship, antibiotics, community-acquired pneumonia,

bacterial infection

Abstract

Literature suggests that antibiotic prescribing in COVID-19 patients is high, despite low rates of confirmed bacterial infection. There are little data on what drives prescribing habits. This retrospective, multi-center, observational study sought to determine antibiotic prescribing rates and risk factors for antibiotic prescribing in hospitalized patients. Patients admitted from March 1, 2020 to May 31, 2020 and treated for PCR-confirmed COVID-19 were included. The primary endpoint was the rate of antibiotic use during hospitalization. Secondary endpoints included risk factors associated with antibiotic use, risk factors associated with receiving more than one antibiotic course, and rate of microbiologically confirmed infections. A total of 208 encounters (198 patients) were included in the final analysis. Eighty-three percent of patients received at least one course of antibiotics, despite low rates of microbiologically confirmed infection (12%). Almost one-third of patients (30%) received more than one course of antibiotics. There was a low rate of respiratory cultures obtained (32%). Risk factors identified in a univariate analysis for both antibiotic prescribing and receiving more than one course of antibiotics were more serious illness, increased hospital length of stay, ICU admission, mechanical ventilation, and ARDS. This study highlights the need for increased antibiotic stewardship practices in COVID-19 patients. Further studies should be conducted to determine the utility of different stewardship initiatives in COVID-19 patients.

Introduction

The novel coronavirus disease identified in 2019 (COVID-19) is caused by a betacoronavirus known as SARS-CoV-2. Despite the fact that COVID-19 is a viral infection, clinical manifestations may present similarly to a bacterial pneumonia.[1] Patients often present with respiratory symptoms including fever, cough, dyspnea, and bilateral changes on chest imaging.[1] It can be difficult to determine if patients have a bacterial respiratory coinfection along with COVID-19 infection. This may lead to over-prescribing of antibiotics in patients with COVID-19.

Despite bacterial coinfection being reported in 2-8% of patients, rates of antibiotic prescribing have ranged from 57-95% in hospitalized patients.[1-7] Additionally, there are reports of increased consumption of antibiotics during the COVID-19 pandemic.[6-9] Over-prescribing of antibiotics may increase the risk of adverse side effects, nosocomial infection, and antibiotic resistance. Several organizational guidelines recommend starting empiric antibiotic therapy if concern for bacterial pneumonia or sepsis, but to re-evaluate daily and de-escalate or discontinue if no evidence of bacterial infection.[10-14] Furthermore, they emphasize the importance of antimicrobial stewardship programs which may help to avoid starting antibiotics reflexively or continuing unnecessary courses. The World Health Organization (WHO) has released guidance which discourages the use of antibiotic therapy for patients with COVID-19 infections unless signs and symptoms of a bacterial infection exist.[11]

Unfortunately, there are limited data to date describing the need or role for antibiotics in COVID-19 or outcomes for patients who receive them. Additionally, little is known regarding

risk factors associated with antibiotic use. There have only been two previous studies which

evaluated prescribing trends, and risk factors of antibiotic prescribing. Both studies focused on

prescribing rates, coinfections and risk factors associated with antibiotic prescribing within the

first 48 hours of admission.[4,5]

The purpose of this study was to evaluate the rate of antibiotic use in COVID-19 patients

and risk factors associated with antibiotic use throughout hospitalization. A better

understanding of prescribing practices can be used to evaluate opportunities for antibiotic

stewardship for future patients with COVID-19.

Methods

Study design

This was a multi-center, retrospective, observational study of antibiotic prescribing

trends in patients with confirmed COVID-19 at three hospitals within the University of

Rochester Medical Center.

Patients 18 years and older admitted from March 1, 2020 to May 31, 2020 and treated

for PCR-confirmed COVID-19 were eligible for inclusion. Patients did not meet inclusion criteria

if they were only treated in the emergency department without subsequent admission. Patients

could be included more than once if they had multiple admissions within the study period.

Patients were excluded if they were asymptomatic. Data were collected until June 30, 2020.

This study was reviewed and deemed exempt by the Institutional Review Board.

Data Collection

Patients were identified from the electronic health record based on a positive or

presumptive positive SARS-CoV-2 PCR test. Baseline data including age, gender, race, weight,

height, comorbidities, date of first positive SARS-CoV-2 PCR, and admission and discharge dates

were collected. Labs on admission (or at time of positive test if nosocomial transmission),

microbiologic data, clinical symptoms, imaging, antibiotic data, COVID-19 investigational or off-

label treatment, death and re-admission within 30 days were also collected.

Outcomes

The primary endpoint of the study was the rate of antibiotic use in patients admitted for

COVID-19. Secondary endpoints included risk factors associated with antibiotic use, risk factors

associated with receiving more than one antibiotic course, and rate of microbiologically-

confirmed infections.

Statistical Analysis

Data were analyzed using R statistical software version 4.0.2 (Boston, MA) with a p-

value < 0.05 considered statistically significant. Continuous variables were described using a

median with interquartile range (IQR). Categorical variables were analyzed using Fisher's exact

testing. Two-sample Wilcoxon test was used for continuous variables. To evaluate risk factors

associated with antibiotic use, a univariate analysis was conducted and variables with a p-value

≤ 0.05 were included in a multivariate logistic regression. In addition, a univariate analysis and

multivariate logistic regression were conducted for patients receiving more than one course of

antibiotics with the following pre-specified variables included if P < 0.05 and clinically

significant: length of stay, intensive care unit (ICU) admission, ICU length of stay, mechanical

ventilation, more than one COVID-19 related admission, microbiologically-confirmed infection,

time from SARS-CoV-2 collection date to initial antibiotic start, and 28-day mortality.

Results:

A total of 228 encounters met inclusion criteria, with twenty excluded due to

asymptomatic disease, leaving 208 encounters included in the final analysis (n=198 patients).

The median age was 69 years (IQR 60-80) and 50% (105/208) were male (Table 1). The most

common comorbidities were hypertension (143/208, 69%), obesity (81/208, 39%), and diabetes

(81/208, 39%). Of 208 encounters, 83% of patients received at least one course of antibiotics.

Antibiotic prescribing did not differ based on gender, age, race, or comorbidities. Even though a

small subset of patients (n=11), all immunocompromised patients received antibiotics (Table 1).

While rates of antibiotic prescribing overall were high, we saw a temporal decrease in

antibiotic prescribing. When consolidating encounters by month of admission, rates of

antibiotic prescribing were highest in March, with 88% (42/49) of encounters receiving

antibiotics, compared to 82% (127/155) in April and 75% (3/4) in May.

Rates of antibiotic prescribing were significantly higher in patients admitted to the ICU,

requiring O2 support (including ventimask, BiPAP and mechanical ventilation), and with acute

respiratory distress syndrome (ARDS) ($p < 0.0001$). Median length of stay was 6.5 days longer in

those receiving antibiotics ($p < 0.0001$). Patients who received investigational or off-label

therapy for COVID-19 were also more often prescribed antibiotics ($p = 0.0328$). Of patients who

died within 28 days, 92% received antibiotics (47/51, p=0.017). Additionally, median aspartate

transaminase (AST), lactate dehydrogenase (LDH), and procalcitonin (PCT) at baseline were

higher in those who were prescribed antibiotics (Table 1). PCT > 0.5 was associated with a

higher rate of antibiotic prescribing [94% (44/47) prescribed antibiotics vs. 6% (3/47) did not

receive antibiotics, OR 3.76, CI 1.09-20.1, p = 0.03]. Of patients with a PCT > 0.5, 43/47 had

respiratory or blood cultures obtained. Microbiologically confirmed bacterial infection was

present in 12% (5/43).

Respiratory cultures were obtained in 32% (67/208) of patients. In total, 19% (13/67)

were positive (Table 2). *Staphylococcus aureus* was identified in 5 (38%) of 13 positive

respiratory culture results (3% of total patients). Blood cultures were obtained in the majority

of patients (149/208, 72%), but few were positive (12/149, 7%). All influenza PCR and *Legionella*

urinary antigen (UAg) tests were negative. Two *Streptococcus pneumoniae* UAg tests were

positive (2.4%, 2/84). In addition, 75 patients (36%) were screened for MRSA nares

colonization. Overall, there were 24 microbiologically-confirmed infections treated with

antibiotics [11% (24/208) overall]. In a subgroup analysis, patients with microbiologically

confirmed infections were more likely to receive more than one course of antibiotics, be

admitted to the ICU, and have a longer length of stay.

The most frequently prescribed initial antibiotics were ceftriaxone in 113 (66%) patients

and azithromycin in 99 (57%) patients for community acquired pneumonia (CAP), followed by

an anti-pseudomonal beta lactam (23%) and vancomycin (23%) for hospital acquired

pneumonia (HAP) or ventilator associated (VAP) (Figures 1 and 2). The median time from SARS-

CoV-2 collection to antibiotic initiation was one day (IQR 1-4.5 days). Median duration of

therapy for the initial course of antibiotics was five days (IQR 2-6 days). In 41 (24%) patients,

the initial regimen was changed; 17 patients were escalated to broader therapy (42%) and15

patients were de-escalated to narrower therapy (37%). Nine (22%) had another regimen change

such as intravenous to oral conversion or changed to another agent with similar spectrum of

activity.

Fifty-two patients (30%) received a second course of antibiotics and 19 patients (11%)

received more than 2 antibiotic courses during hospitalization. The most frequently prescribed

antibiotics included an anti-pseudomonal beta lactam (58%) and vancomycin (58%) for

HAP/VAP (Figures 1 and 2). The median duration of second course antibiotics was 6 days (IQR 3-

8.25). Duration of admission, ICU admission, ICU LOS, mechanical ventilation, microbiologically

confirmed infection, and duration of initial course of antibiotics were all risk factors for

receiving more than one course of antibiotics (Table 3). Based on the number of patients

receiving more than one course of antibiotics, and of the variables that were both statistically

significant and clinically relevant on univariate analysis, we chose to include ICU admission,

mechanical ventilation, microbiologically confirmed infection, duration of admission and ICU

LOS in our multivariate analysis. ICU length of stay was the only variable found to be a

statistically significant in the multivariate analysis. (Table 4).

Discussion

In this multi-center study of patients hospitalized with COVID-19, we found an overall

high rate of antibiotic prescribing, with 83% of patients receiving antibiotics. Of these patients,

30% received at least one additional course of antibiotics during hospitalization, increasing the

overall antibiotic exposure. Despite the high rate of antibiotic prescribing, there were low rates

of bacterial coinfection, with only 12% of patients having microbiologically confirmed infection.

These findings are similar to the results of previous studies, suggesting the need for strategies

to help clinicians judiciously prescribe antibiotics in patients with COVID-19.[1-5,15] Interestingly,

while still low, our rate of bacterial coinfection was higher compared to other US studies.

Compared to these previous studies, we had higher rates of ICU admission and mechanically

ventilated patients.[4,5] In our study, we reported microbiologic data throughout hospitalization,

and even during multiple admissions whereas these two previous studies only reported the first

48 hours. This likely contributed to higher rates of microbiologically confirmed infections in our

study. Patients with microbiologically confirmed infections were more likely to receive more

than one course of antibiotics, be admitted to the ICU, and have a longer length of stay. While

this may suggest patients with bacterial coinfection are more likely to have serious illness, the

higher rate of microbiologically confirmed infections may also be explained by bacterial

infections acquired during hospitalization. Additional courses of antibiotics were often

prescribed for empiric or targeted treatment of nosocomial infection.

Early in the pandemic, little was known regarding COVID-19 presentation and disease

progression. Additionally, there was a paucity of data suggesting bacterial co-infection was low

in the beginning of the COVID-19 pandemic. Thus, guideline recommendations were evolving

throughout the study period. Initial recommendations often encouraged antibiotic use. Within

the University of Rochester Medical Center, our practices and institutional guidelines

recommended initiating empiric antibiotics in the majority of COVID-19 patients. As information

became more available, and recommendations changed, our antibiotic prescribing decreased.

This was reflected in the temporal decline in antibiotic prescribing we observed from March to

May.

There were several indicators that serious illness increased the risk of antibiotic

prescribing. Initial antibiotic prescribing was more likely in patients with certain elevated

laboratory values (PCT, AST, and LDH), longer length of stay, ICU admission, longer ICU length of

stay, and administration of off-label or investigational therapy for COVID-19. Additionally, all

patients with ARDS or requiring more invasive O2 support received at least 1 course of

antibiotics. These findings are consistent with previous studies which found patients were more

likely to receive antibiotics if they had severe disease upon presentation.[4,5] To our knowledge,

this is the first study to report rates of additional antibiotic prescribing beyond initial empiric

therapy. Patients with COVID-19 often have a prolonged hospitalization due to the underlying

disease process. Our median LOS was significantly longer in patients which received at least one

antibiotic course (p < 0.001), and prolonged hospitalization may also increase the potential for

additional antibiotic exposure. Thus, it is important to understand antibiotic prescribing trends

and associated risk factors beyond the first course. Our study found that nearly one-third of all

patients received two or more courses of antibiotics. Variables associated with receiving two or

more antibiotic courses included: longer length of stay, ICU admission, longer ICU length of

stay, and mechanical ventilation. This is likely explained as these are all risk factors for hospital-

acquired illness and antibiotics were commonly prescribed for nosocomial infection (e.g.

HAP/VAP).

Procalcitonin has been suggested as a potentially useful biomarker to differentiate

bacterial and viral infections and assist with clinical decision-making. A Cochrane review of

acute respiratory infections concluded that use of procalcitonin to guide treatment decisions

results in lower antibiotic consumption, lower mortality, and fewer antibiotic-related side

effects.[16] In contrast, a recent study in pneumonia comparing procalcitonin-guided treatment

and usual care found no difference in duration of antibiotic treatment or antibiotic-associated

outcomes.[17] The ATS/IDSA CAP guidelines strongly advise initiating antibiotics based off clinical

judgement rather than procalcitonin alone.[13] In COVID-19 patients specifically, a recent

retrospective cohort study found that patients with COVID-19 consistently had negative

procalcitonin levels (< 0.25 ng/mL).[18] Conversely, elevated procalcitonin levels have been

associated with severity of illness or mortality.[19] Elevated procalcitonin may represent bacterial

coinfection, but could also be due to immune dysregulation.[20] At our sites, the patients

prescribed antibiotics had significantly higher baseline procalcitonin, however the median was

only 0.28. In a subgroup analysis focusing on patients who had a procalcitonin of > 0.5, 94% of

patients received antibiotics. It is unclear at this time the utility of using procalcitonin to

determine if there is bacterial co-infection with COVID-19.

Previous studies have shown high rates of broad-spectrum antibiotics for initial empiric

therapy in COVID-19 patients.[1,3-6,8,15] However, in our patient population, most patients were

treated initially for CAP. The most common agents included ceftriaxone plus azithromycin,

which is consistent with the 2019 ATS/IDSA recommendations for CAP.[13] During the initial

antibiotic course, 36.6% of patients were de-escalated to narrower therapy. Not surprisingly,

patients that received a second course of antibiotics were more likely to receive broad-

spectrum antimicrobials; over half of patients who received more than one course of antibiotics

were treated for HAP/VAP and prescribed an anti-pseudomonal beta lactam (i.e cefepime or

piperacillin/tazobactam.) Respiratory cultures were obtained in only 30.2% of patients, with a

large number of patients receiving empiric treatment for CAP, HAP or VAP. In part, the low

number of respiratory cultures obtained may be due to the symptomatology of disease, with

the majority of patients experiencing dry, non-productive cough.[1] Additionally, early in the

pandemic, there were concerns regarding transmission and aerosolization, which added

additional challenges to obtaining respiratory cultures. In addition, the 2019 ATS/IDSA CAP

guidelines do not recommend routine sputum gram stain and culture in patients with non-

severe CAP or those without multi-drug resistant organism risk factors due to overall poor yield

and detection of organisms.[13] However, respiratory cultures are recommended in patients

being treated empirically for MDR organisms, and in those being treated for HAP/VAP.[13,14]

Respiratory cultures were not obtained in all patients who met these criteria. Obtaining

respiratory cultures and other microbiologic data, when possible, on patients treated with

broad spectrum antibiotics can potentially help with de-escalation of therapy.

One limitation of this study is its retrospective design. Laboratory and microbiologic

data collected were not consistent amongst all patients. We found duration of admission and

ICU length of stay to be associated with higher antibiotic use, however it is difficult to say that

these are true risk factors for antibiotic prescribing. Instead, this difference was likely due to

antibiotic prescribing being higher in patients with more serious illness, and perhaps longer

admission leading to increased risk of nosocomial infections and subsequent antibiotic courses.

Additionally, we did not perform a time adjusted analysis. Another limitation is that the vast

majority of patients within our study received antibiotics which could have affected our ability

to detect differences between the two groups.

While there were limitations of this study, there were also several strengths. This study

was multi-site, including three hospitals within the University of Rochester Medical Center: two

community hospitals and a tertiary academic medical center. Therefore, the results of this

study may be generalizable to similar sites. Finally, as previously mentioned, this is the first

study to assess overall antibiotic use throughout hospitalization, and determine risk factors for

additional antibiotic courses. Many patients with COVID-19 have prolonged hospitalization,

increasing the risk for antibiotic exposure. Our study examined antibiotic use that is more

representative of hospitalized COVID-19 patients.

Conclusions

Our study found high rates of antibiotic prescribing, despite low rates of respiratory

cultures and confirmed microbiologic infections. Antibiotic prescribing was higher in patients

with elevated PCT, longer LOS, ICU admission, 28-day mortality, investigational or off-label

treatment for COVID-19, ARDS, and invasive O2 support. Nearly one-third of patients were

treated with more than one antibiotic course during hospitalization. Patients who received two

or more antibiotic courses were more likely to have longer ICU LOS as demonstrated by the

multivariate analysis. These data highlight a role for antimicrobial stewardship during the

COVID-19 pandemic. Further studies are needed to examine the impact of antimicrobial

stewardship initiatives in patients with COVID-19 and assess if antibiotic prescribing practices

have changed with increasing information related to bacterial co-infection that wasn't available

at the beginning of the pandemic.

Acknowledgements

The authors thank Raquel Roberts, PharmD for her assistance with data collection. There was

no funding for the study. The authors report no conflict of interest.

Tables and Figures

Table 1. Baseline Characteristics of COVID-19 patients and Risk factors for Antibiotic Prescribing				
Baseline Characteristic	**Total**	**Antibiotics n=172**	**No Antibiotics n=36**	**P-value**
Male gender	105 (50.5)	84 (48.8)	21 (55.6)	0.43
Age, years (median, IQR)	69.0 (60-80)	70.0 (61-81)	65.5 (47-77)	0.12
Race				0.56
Caucasian	116 (55.7)	98 (56.9)	18 (47.2)	
Black/African American	69 (33.2)	53 (30.8)	16 (44.4)	
Asian	2 (1.0)	2 (1.2)	0 (0)	
Other	6 (2.9)	6 (3.5)	0 (0)	
Unknown	15 (7.2)	13 (7.6)	2 (5.6)	
Comorbidities				
Hypertension	143 (68.8)	116 (67.4)	27 (72.2)	0.43
Diabetes	81 (38.9)	70 (23.2)	11 (27.8)	0.35
Obesity	80 (38.5)	66 (38.4)	14 (38.9)	>0.99
Cardiac Disease	56 (26.9)	50 (29.1)	6 (16.7)	0.15
Chronic Lung Disease	43 (20.7)	37 (21.5)	6 (16.7)	0.65
CKD	45 (21.7)	40 (23.2)	5 (13.9)	0.20
None	21 (10.1)	17 (9.9)	4 (11.1)	0.77
Immunocompromised[a]	11 (5.3)	11 (6.4)	0 (0)	0.22
Labs (median, IQR)				
AST, U/L	43 (31-65)	46 (33.25-65)	35 (26.75-49)	0.02
ALT, U/L	30 (20-46)	29.5 (20-45)	32.5 (20-49.5)	0.83
Scr, mg/dL	1.130 (0.84-1.64)	1.14 (0.84-1.725)	1.06 (0.81-1.3)	0.14
WBC	7.30 (5.50-10.50)	7.4 (5.5-10.7)	6.8 (4.8-9.2)	0.11
ALC	1.0 (0.7-1.3)	1.0 (0.7-1.3)	1.1 (0.5-1.4)	0.10
CRP	93.0 (39.5-134.5)	93 (39.5-134.5)	73 (37.5-118.5)	0.37
LDH	344 (264.5-467)	348 (285-474)	294 (239-387)	0.03
Ferritin	627 (304-1086)	627 (309-1133.5)	589 (235-980)	0.45

D-dimer	1.26 (0.63-2.08)	1.37 (0.71-2.1)	0.86 (0.6-1.6)	0.24
PCT	0.215 (0.120-0.620)	0.28 (0.13-0.63)	0.13 (0.09-0.20)	<0.01
Symptoms Prior to Admission				
Fever	120 (57.7)	101 (58.7)	19 (52.8)	0.59
Respiratory Symptoms	180 (86.5)	152 (88.4)	28 (75)	0.10
Gastrointestinal symptoms	76 (36.5)	60 (34.9)	16 (41.7)	0.34
Anosmia/Hyperosmia/Hypogeusia	11 (5.3)	10 (5.8)	1 (2.8)	0.69
Symptom duration prior to admission, days (median, IQR)	6.0 (3-9)	6.0 (3-9)	7.5 (4.75-9)	0.16
Location prior to admit				0.08
Home	140 (67.3)	110 (63.9)	30 (80.5)	
SNF	60 (28.8)	54 (31.4)	6 (16.7)	
Transfer from OSH	8 (3.8)	8 (4.7)	0 (0)	
Duration of admission, days (median, IQR)	11 (5-22)	12 (5.75-25)	5.5 (4-11.3)	<0.01
ICU admission	104	102 (58.9)	2 (5.6)	<0.01
ICU LOS, days (median, IQR)	10 (3-18)	10 (3.25-18)	6.5 (6.25-6.75)	0.59
O2 support				<0.01
Room Air	40 (19.2)	24 (13.9)	16 (44.4)	
Standard Nasal Cannula	67 (32.2)	49 (28.5)	18 (50.0)	
HFNC/Venti Mask	19 (9.1)	17 (9.9)	2 (5.6)	
BiPAP	5 (2.4)	5 (2.9)	0 (0)	
Non-rebreather	7 (3.4)	7 (4.1)	0 (0)	
Mechanical ventilation	70 (33.7)	70 (40.7)	0 (0)	
ARDS	78 (37.5)	78 (45.3)	0 (0)	<0.01
Received investigational or off-label transfer for COVID-19	37 (17.8)	35 (20.2)	2 (5.6)	0.03
28-day mortality	51 (24.5)	48 (27.9)	3 (8.3)	0.02
30-day readmission	16 (7.7)	12 (6.9)	4 (11.1)	0.75
More than 1 admission for COVID-19	12 (5.8)	8 (4.7)	4 (11.1)	0.23
Time from discharge to COVID-19 readmission, days (median, IQR)	7 (4.5-12.25)	5 (2.75-11.5)	10 (7.75-12.5)	0.22

()= Percentages unless otherwise specified
a = immunocompromised patients were defined as those with previous solid organ transplant, active cancer receiving chemotherapy, patients on biologic therapy, and uncontrolled HIV
IQR = Interquartile Range
CKD = chronic kidney disease
AST = Aspartate aminotransferase
ALT = Alanine aminotransferase
SCr= Serum Creatinine
WBC = White blood cell count
ALC = Absolute lymphocyte count
CRP = C-reactive protein
LDH= Lactate dehydrogenase
PCT = procalcitonin
SNF = Skilled nursing facility
HFNC = high flow nasal cannula
Respiratory symptoms were defined as hypoxia, SOB, cough

299   GI symptoms were defined as nausea, vomiting, diarrhea
300

Table 2: Microbiologic Data			
Micro Data	Antibiotics n=172	No antibiotics n=36	P-value
Microbiologically-confirmed infection	24 (14.0)	0 (0)	0.02
Respiratory cultures obtained	66 (38.3)	1 (2.7)	<0.01
No growth	53 [80.3]	1 [100]	>0.99
Positive	13 [19.7]	0 [0]	>0.99
Blood cx obtained	135 (78.5)	14 (38.9)	<0.01
No growth	123 [91.1]	14 [100]	0.61
Positive	12 [8.9]	0 [0]	0.61
Influenza PCR obtained	75 (43.6)	13 (36.1)	0.46
Strep pneumoniae urinary antigen obtained	82 (47.7)	6 (16.7)	<0.01
Positive	2 [2.4]	0 [0]	>0.99
Negative	80 [97.6]	6 [100]	>0.99
Legionella urinary antigen obtained	87 (50.5)	6 (16.7)	<0.01
MRSA nares obtained	73 (42.4)	2 (5.6)	<0.01
Positive	4 [5.5]	0 [0]	>0.99
Negative	69 [94.5]	2 [100]	>0.99

303   ()= percent unless otherwise specified

Figure 1: Antibiotic Prescribing Trends

Figure 2: Indications for Antibiotic Prescribing

CAP= community acquired pneumonia
HAP= hospital acquired pneumonia
VAP= ventilator associated pneumonia
BSI = blood stream infection

Table 3: Risk factors associated with receiving more than 1 course of antibiotics						
	Univariate Analysis			Multivariate analysis		
Variable	1 antibiotic course n= 120 (%)	> 1 antibiotic course n=52 (%)	P value	Odds ratio	95% CI	P-value
Length of stay, days (median, IQR)	8 (4-15)	25 (18.75-37)	<0.01	1.01	0.99-1.04	0.32
ICU admission	51 (42.5)	49 (94.2)	<0.01	1.96	0.38-11.10	0.42
ICU length of stay, days (median, IQR)	5 (3-9)	18 (12-26)	<0.01	1.14	1.06-1.26	<0.01
Mechanical ventilation	25 (20.8)	45 (86.5)	<0.01	1.83	0.46-7.61	0.39
More than 1 COVID-19 related admission	7 (5.8)	1 (1.9)	0.44			
Microbiologically-confirmed infection	4 (3.3)	20 (38.5)	<0.01	3.31	0.86-15.26	0.10
Duration of initial course of antibiotics, days (median, IQR)	4 (2-5.25)	5 (4-7)	<0.01			
Time from SARS-CoV-2 collect date	1 (0-5)	2 (0-2)	0.51			

to initial antibiotic start, days (median, IQR)						
28-day mortality	33 (27.5)	14 (38.9)	>0.99			

()= Percentages unless otherwise specified

References:

1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 2020;395:1054-62.
2. Crotty MP, Dominguez EA, Akins R, et al. Investigation of subsequent and co-infections associated with SARS-CoV-2 (COVID-19) in hospitalized patients. medRxiv 2020.
3. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020.
4. Vaughn VM, Gandhi T, Petty LA, et al. Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study. 2020.
5. Wei W, Ortwine JK, Mang NS, Joseph C, Hall BC, Prokesch BC. Limited Role for Antibiotics in COVID-19: Scarce Evidence of Bacterial Coinfection. Available at SSRN 3622388 2020.
6. Beović B, Doušak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey. Journal of Antimicrobial Chemotherapy 2020.
7. Buehrle DJ, Decker BK, Wagener MM, et al. Antibiotic consumption and stewardship at a hospital outside of an early Coronavirus disease 2019 epicentre. 2020:AAC.01011-20.
8. Abelenda-Alonso G, Padullés A, Rombauts A, et al. Antibiotic prescription during the COVID-19 pandemic: A biphasic pattern. Infection Control & Hospital Epidemiology 2020:1-2.
9. Nestler M, Godbout E, Lee K, et al. Impact of COVID-19 on Pneumonia-Focused Antibiotic Use at an Academic Medical Center. Infection control and hospital epidemiology 2020:1-9.
10. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health

11. Clinical management of COVID-19 Interim Guidance - May 2020. World Health Organization. 2020, at https://www.who.int/publications-detail/clinical-management-of-covid-19.)
12. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive care medicine 2020;46:854-87.
13. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. 2019;200:e45-e67.
14. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases 2016;63:e61-e111.
15. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. The Journal of infection 2020;81:266-75.
16. Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. The Cochrane database of systematic reviews 2017;10:Cd007498.
17. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. 2018;379:236-49.
18. Bass J, Singh A, Williams R, Lindner DH. Procalcitonin and COVID-19: A Reliable Clinical Tool. 2020.
19. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. International journal of antimicrobial agents 2020;56:106051.
20. Shah V. Advances in Motion 2020.

Tables and Figures

Table 1. Baseline Characteristics of COVID-19 patients and Risk factors for Antibiotic Prescribing				
Baseline Characteristic	Total	Antibiotics n=172	No Antibiotics n=36	P-value
Male gender	105 (50.5)	84 (48.8)	21 (55.6)	0.43
Age, years (median, IQR)	69.0 (60-80)	70.0 (61-81)	65.5 (47-77)	0.12
Race				0.56
Caucasian	116 (55.7)	98 (56.9)	18 (47.2)	
Black/African American	69 (33.2)	53 (30.8)	16 (44.4)	
Asian	2 (1.0)	2 (1.2)	0 (0)	
Other	6 (2.9)	6 (3.5)	0 (0)	
Unknown	15 (7.2)	13 (7.6)	2 (5.6)	
Comorbidities				
Hypertension	143 (68.8)	116 (67.4)	27 (72.2)	0.43
Diabetes	81 (38.9)	70 (23.2)	11 (27.8)	0.35
Obesity	80 (38.5)	66 (38.4)	14 (38.9)	>0.99
Cardiac Disease	56 (26.9)	50 (29.1)	6 (16.7)	0.15
Chronic Lung Disease	43 (20.7)	37 (21.5)	6 (16.7)	0.65
CKD	45 (21.7)	40 (23.2)	5 (13.9)	0.20
None	21 (10.1)	17 (9.9)	4 (11.1)	0.77
Immunocompromised[a]	11 (5.3)	11 (6.4)	0 (0)	0.22
Labs (median, IQR)				
AST, U/L	43 (31-65)	46 (33.25-65)	35 (26.75-49)	0.02
ALT, U/L	30 (20-46)	29.5 (20-45)	32.5 (20-49.5)	0.83
Scr, mg/dL	1.130 (0.84-1.64)	1.14 (0.84-1.725)	1.06 (0.81-1.3)	0.14
WBC	7.30 (5.50-10.50)	7.4 (5.5-10.7)	6.8 (4.8-9.2)	0.11
ALC	1.0 (0.7-1.3)	1.0 (0.7-1.3)	1.1 (0.5-1.4)	0.10
CRP	93.0 (39.5-134.5)	93 (39.5-134.5)	73 (37.5-118.5)	0.37
LDH	344 (264.5-467)	348 (285-474)	294 (239-387)	0.03
Ferritin	627 (304-1086)	627 (309-1133.5)	589 (235-980)	0.45
D-dimer	1.26 (0.63-2.08)	1.37 (0.71-2.1)	0.86 (0.6-1.6)	0.24
PCT	0.215 (0.120-0.620)	0.28 (0.13-0.63)	0.13 (0.09-0.20)	<0.01
Symptoms Prior to Admission				
Fever	120 (57.7)	101 (58.7)	19 (52.8)	0.59
Respiratory Symptoms	180 (86.5)	152 (88.4)	28 (75)	0.10

Gastrointestinal symptoms	76 (36.5)	60 (34.9)	16 (41.7)	0.34
Anosmia/Hyperosmia/Hypogeusia	11 (5.3)	10 (5.8)	1 (2.8)	0.69
Symptom duration prior to admission, days (median, IQR)	6.0 (3-9)	6.0 (3-9)	7.5 (4.75-9)	0.16
Location prior to admit				0.08
Home	140 (67.3)	110 (63.9)	30 (80.5)	
SNF	60 (28.8)	54 (31.4)	6 (16.7)	
Transfer from OSH	8 (3.8)	8 (4.7)	0 (0)	
Duration of admission, days (median, IQR)	11 (5-22)	12 (5.75-25)	5.5 (4-11.3)	<0.01
ICU admission	104	102 (58.9)	2 (5.6)	<0.01
ICU LOS, days (median, IQR)	10 (3-18)	10 (3.25-18)	6.5 (6.25-6.75)	0.59
O2 support				<0.01
Room Air	40 (19.2)	24 (13.9)	16 (44.4)	
Standard Nasal Cannula	67 (32.2)	49 (28.5)	18 (50.0)	
HFNC/Venti Mask	19 (9.1)	17 (9.9)	2 (5.6)	
BiPAP	5 (2.4)	5 (2.9)	0 (0)	
Non-rebreather	7 (3.4)	7 (4.1)	0 (0)	
Mechanical ventilation	70 (33.7)	70 (40.7)	0 (0)	
ARDS	78 (37.5)	78 (45.3)	0 (0)	<0.01
Received investigational or off-label transfer for COVID-19	37 (17.8)	35 (20.2)	2 (5.6)	0.03
28-day mortality	51 (24.5)	48 (27.9)	3 (8.3)	0.02
30-day readmission	16 (7.7)	12 (6.9)	4 (11.1)	0.75
More than 1 admission for COVID-19	12 (5.8)	8 (4.7)	4 (11.1)	0.23
Time from discharge to COVID-19 readmission, days (median, IQR)	7 (4.5-12.25)	5 (2.75-11.5)	10 (7.75-12.5)	0.22

()= Percentages unless otherwise specified
a = immunocompromised patients were defined as those with previous solid organ transplant, active cancer receiving chemotherapy, patients on biologic therapy, and uncontrolled HIV
IQR = Interquartile Range
CKD = chronic kidney disease
AST = Aspartate aminotransferase
ALT = Alanine aminotransferase
SCr= Serum Creatinine
WBC = White blood cell count
ALC = Absolute lymphocyte count
CRP = C-reactive protein
LDH= Lactate dehydrogenase
PCT = procalcitonin
SNF = Skilled nursing facility
HFNC = high flow nasal cannula
Respiratory symptoms were defined as hypoxia, SOB, cough
GI symptoms were defined as nausea, vomiting, diarrhea

Table 2: Microbiologic Data			
Micro Data	Antibiotics n=172	No antibiotics n=36	P-value
Microbiologically-confirmed infection	24 (14.0)	0 (0)	0.02
Respiratory cultures obtained	66 (38.3)	1 (2.7)	<0.01
No growth	53 [80.3]	1 [100]	>0.99
Positive	13 [19.7]	0 [0]	>0.99
Blood cx obtained	135 (78.5)	14 (38.9)	<0.01
No growth	123 [91.1]	14 [100]	0.61
Positive	12 [8.9]	0 [0]	0.61
Influenza PCR obtained	75 (43.6)	13 (36.1)	0.46
Strep pneumoniae urinary antigen obtained	82 (47.7)	6 (16.7)	<0.01
Positive	2 [2.4]	0 [0]	>0.99
Negative	80 [97.6]	6 [100]	>0.99
Legionella urinary antigen obtained	87 (50.5)	6 (16.7)	<0.01
MRSA nares obtained	73 (42.4)	2 (5.6)	<0.01
Positive	4 [5.5]	0 [0]	>0.99
Negative	69 [94.5]	2 [100]	>0.99

()= percent unless otherwise specified

[]= percent of subset

Figure 1: Antibiotic Prescribing Trends

Figure 2: Indications for Antibiotic Prescribing

CAP= community acquired pneumonia
HAP= hospital acquired pneumonia
VAP= ventilator associated pneumonia
BSI = blood stream infection

Table 3: Risk factors associated with receiving more than 1 course of antibiotics						
	Univariate Analysis			Multivariate analysis		
Variable	1 antibiotic course n= 120 (%)	> 1 antibiotic course n=52 (%)	P value	Odds ratio	95% CI	P-value
Length of stay, days (median, IQR)	8 (4-15)	25 (18.75-37)	<0.01	1.01	0.99-1.04	0.32
ICU admission	51 (42.5)	49 (94.2)	<0.01	1.96	0.38-11.10	0.42
ICU length of stay, days (median, IQR)	5 (3-9)	18 (12-26)	<0.01	1.14	1.06-1.26	<0.01
Mechanical ventilation	25 (20.8)	45 (86.5)	<0.01	1.83	0.46-7.61	0.39
More than 1 COVID-19 related admission	7 (5.8)	1 (1.9)	0.44			
Microbiologically-confirmed infection	4 (3.3)	20 (38.5)	<0.01	3.31	0.86-15.26	0.10
Duration of initial course of antibiotics, days (median, IQR)	4 (2-5.25)	5 (4-7)	<0.01			
Time from SARS-CoV-2 collect date to initial antibiotic start, days (median, IQR)	1 (0-5)	2 (0-2)	0.51			
28-day mortality	33 (27.5)	14 (38.9)	>0.99			

()= Percentages unless otherwise specified